🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the pathogen, according to researchers.

A Global Health Concern

The sexually transmitted infection are on the rise around the world, with figures suggesting in excess of 82 million instances annually. Especially elevated rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary advancement in the face of rising global incidence, escalating drug resistance and the extremely scarce therapeutic options presently on offer.”

Health officials are deeply concerned about the increase in antibiotic-resistant strains. The global health body has listed it as a "priority pathogen". A tracking program showed that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Gain Approval

One new antibiotic, also known as Nuzolvence, was approved by the American regulatory agency in mid-December for use against gonorrhoea. This infection can lead to major issues, including infertility. Scientists anticipate that focused deployment of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This medication, which is also used to treat UTIs, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to see it through.

“This milestone marks a significant shift in the management of highly resistant gonorrhoea, which until now has been staying ahead of medical innovation.”

Clinical Trial Results and Global Access

According to results detailed in a prominent scientific publication, the new drug eradicated over nine in ten of genital gonorrhoea infections. This establishes an comparable level with the existing first-line therapy, which uses a dual-drug approach. The research enrolled nearly 1,000 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the rights to make available and distribute the drug in many low-income and middle-income countries.

Doctors on the front lines have expressed positive views. The availability of a single-dose, oral treatment of this kind is hailed as a "revolutionary step" for gonorrhoea control. This is viewed as vital to reduce the burden of the disease for individuals and to prevent the spread of untreatable gonorrhoea around the world.